Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology

AI Briefing

• – Nanobiotix reports positive preclinical data on LNP-delivered DNA immunotherapy
• – New data show improved systemic bioavailability and reduced toxicity
• – Results presented at American Association for Cancer Research 2026 Annual Meeting